@sanderhamburger@CscottLawyer@BryantSmit51765 Haha, $NWBO has said many things in their PRs that have been just pure BS. They BS more than the truth. Just like multiple regulatory applications soon after MAA submission. Like that new Direct trial in 2017. You’re living in denial as you have been trapped for many years. $NWBO
@CscottLawyer@sanderhamburger@BryantSmit51765 Because the concerns expressed around efficacy is not fixable without a new confirmatory study. Only way out may be political pressure forcing MHRA to strike a middle ground. So $NWBO will use the 6 months clock off to build political pressure & then appear in Feb-Mar 2027. $NWBO
@CscottLawyer@sanderhamburger@BryantSmit51765 Because of the political pressure. Once it’s officially confirmed that they skipped Sept CHM, this reinforces my theory that efficacy is still not convincing. If the remaining concerns were trivial then they would’ve appeared in Sept. We know they skipped Oct. $NWBO
$NWBO Expect the short interest to go up as soon as the September CHM minutes are released. It’s clear they didn’t appear at October CHM.
December is a tax loss selling month for baggies. Plus LP diluting 40M+ shares per month. All of this adds fuel to the fire! ;) $NWBO
@SouthernDrive21@Hoofmann6383@NorthwestBio Expect the short volume to climb as it becomes clear $NWBO skipped Sept CHM. We already know they’re not at Oct meeting. Efficacy concerns loom large. Expect a 6 month clock off period again to allow political pressure to build. Conditional approval at best in Q2 2027 or later.
$NWBO, 50%+ downside is on the cards in the next month or two as efficacy concerns loom. Tax loss selling approaching next month. Then around mid 2027 one can expect a request for increase in billion odd shares. That would again be an excellent opportunity to make easy money! ;)
@RHINOBOY66@alphavestcap You don’t deny access to an effective therapy to 200 patients because you cant meet demand for 2000. Flaskworks ain’t getting approved for commercial production for 18 months. Even that is optimistic. It’s more likely to get delayed further or get shelved altogether. $NWBO 2/2
@RHINOBOY66@alphavestcap Liar. It would be unethical to hold off approval due to volume constraints. No regulatory agency would do that. KITE could only produce dose for 100 patients in the 1st year post FDA approval. RAs focus on safety and efficacy. Efficacy has been the issue with $NWBO. 1/2
$NWBO, it becomes increasingly clear that the new & previous IR persons (Richard and GZ) lied to a few shareholders. Even though they knew that $NWBO didn't appear at Sept CHM they lied that they expect a decision before Nov 15 10-Q. Why would anyone trust these BS artists? $NWBO
@sanderhamburger@BryantSmit51765@CscottLawyer It appears you have been living in denial for many years with this bad investment decision trying to justify that this is not about efficacy & that the company will get unconditional approval.
It ain’t happening. Conditional at best in Q2 2027 or later. See you then! $NWBO 2/2
@sanderhamburger@BryantSmit51765@CscottLawyer Nope. You lost the argument around MIA. Show me the difference between 2025 & 2026 version. You wont! NICE is important because their growth hinges on it. If efficacy wasn’t an issue they would have submitted evidence to NICE in Sept, if not last year! $NWBO 1/2
@sanderhamburger@BryantSmit51765@CscottLawyer Are if these so called other issues were that complex and time consuming (3 years to resolve) then that would be material news. Sometimes the answer is simple. They were asked to come up with patient level data and that was still not fully convincing. $NWBO 2/2
@sanderhamburger@BryantSmit51765@CscottLawyer You’re asking the wrong question. Why haven’t they submitted reimbursement evidence 3 years into the application if it was slam dunk around efficacy? Why would other issue such as manufacturing & CMC take 3 years to address given years of hands on experience at Advent? $NWBO 1/2
@sanderhamburger@BryantSmit51765@CscottLawyer Another hint: no NICE reimbursement evidence submission, 3 years into the application. Because efficacy (or benefit) is the concern. One final hint: they won’t be at the November CHM either! ;) $NWBO
@sanderhamburger@BryantSmit51765@CscottLawyer Nope, they had the same commercial certification license for biological live cells in Dec 2025 & also in Feb 2025. Same certification number. NHSBT was never really the bottleneck as that could have been addressed in 2025 or 2024. It’s always been about efficacy. $NWBO
@sanderhamburger@BryantSmit51765@CscottLawyer Haha nice save! Just wait and watch as one of the indications get rejected and the other gets conditional approval at best. You’re welcome to find new excuses around manufacturing then! ;) $NWBO
@sanderhamburger@BryantSmit51765@CscottLawyer I will give you another hint as to why this is all about efficacy. It will only get conditional approval for one indication. Second indication will simply stay in compassionate use. If the hold up was manufacturing then both ought to get the same verdict, but it won’t. $NWBO
@sanderhamburger@BryantSmit51765@CscottLawyer I’d bet that Advent’s senior team knows considerably more about DCVax-L & real-world cellular therapy manufacturing than Farzin, given their years of hands-on experience. Advent’s certification for commercial production provides strong evidence of its capabilities. $NWBO 2/2